Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)

Read Book : https://centerofsound.blogspot.com/?oak=0849307449

Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have fewer extrapyramidal side effects, are less sedating, and attempt to address the negative symptoms of schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications presents a glimpse into the development of these breakthroughs and the field's current status in one definitive volume.The exhaustive chapters cover the basic knowledge of schizophrenic syndromes and provide a general description of available antipsychotic drugs. Leading specialists recount th

READ PDF Neurotransmitter Receptors in Actions of Antipsychotic Medications (Han

Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)

Read Book : https://centerofsound.blogspot.com/?oak=B00UVA0JBO

Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have fewer extrapyramidal side effects, are less sedating, and attempt to address the negative symptoms of schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications presents a glimpse into the development of these breakthroughs and the field's current status in one definitive volume.The exhaustive chapters cover the basic knowledge of schizophrenic syndromes and provide a general description of available antipsychotic drugs. Leading specialists recount th

PDF BOOK Neurotransmitter Receptors in Actions of Antipsychotic Medications (Han

Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)

Read Book : tq.filegood.club/0849307449

Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia

PDF Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacolog

Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)

Read Book : tq.filegood.club/B00UVA0JBO

Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia

Audiobook Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharm

2-Me-PVP cas: 850352-54-4 chemically known as 2-Methyl-alpha-PVP, is a substituted cathinone derivative with stimulant effects. This compound was first identified in Sweden in 2021 and has been sold as a designer drug. It belongs to the cathinone class, a group known for their stimulating properties, and is developed as a replacement for alpha-PVP, with a similar structure and effects. It is considered a methylated analogue of alpha-PVP. However, it is important to note that 2-Me-PVP has never been clinically tested in humans, and there is limited data available on its pharmacological properties. In terms of its mechanism of action, 2-Me-PVP acts as an inhibitor of dopamine and norepinephrine reuptake, which can lead to effects such as stimulation, concentration in low doses, energy, and euphoria, as observed in rodent studies. It is important to be aware that this substance is banned for sale in some countries, including Germany and the United Kingdom, due to its potential risks​
Similar Competitive Products
Products similar to 2-Me-PVP include other synthetic cathinones and derivatives such as alpha-PVP, MDPV (Methylenedioxypyrovalerone), and other designer drugs with stimulant properties.

Potential Health Benefits and Effects
As a stimulant, 2-Me-PVP may offer temporary increases in energy and concentration, similar to other substances in its class. However, due to the lack of clinical studies in humans, any potential health benefits are speculative and unverified.

Product Mechanism
2-Me-PVP works by inhibiting the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the brain. This results in stimulant effects.

Safety and Side Effects
The safety profile of 2-Me-PVP is not well established due to the lack of clinical testing. Potential side effects could include those typically associated with stimulants, such as increased heart rate, agitation, and risk of addiction.

Dosing Information
There is no established dosing information for 2-Me-PVP, and using it poses significant risks due to its unknown potency and effects.

Contraindications
Given its stimulant nature and unknown safety profile, 2-Me-PVP should be contraindicated for individuals with cardiovascular issues, a history of substance abuse, or psychiatric disorders.

Conclusion
2-Me-PVP is a novel psychoactive substance with stimulant effects but comes with significant uncertainties regarding its safety, efficacy, and legal status. Until more research is conducted, its use remains risky and largely unadvised.

2-Me-PVP cas: 850352-54-4 A New Stimulant on the Horizon - Risks and Unknowns

DELUSIONS

2080 - Connecting the device [loop]

https://www.hanf-magazin.com/wissenschaft/studien/dopaminspiegel-schuld-an-cannabispsychosen/

Eine aktuelle Studie der McGill University in Kanada legt nahe, dass starker und anhaltender THC-Konsum den Dopaminspiegel in bestimmten Hirnregionen erhöht, die mit der Entstehung von Psychosen in Verbindung stehen. Besonders auffällig: Die gemessenen Dopaminwerte bei starken Cannabiskonsumenten ähnelten jenen von Patienten mit beginnender Schizophrenie. Die Forschung zeigt damit eine klare Verbindung zwischen neurobiologischen Vorgängen und exzessivem Cannabiskonsum. Aufklärung, vor allem für Jugendliche, wird dadurch noch wichtiger. Gerade in Zeiten der Legalisierung sollten die Risiken offen und wissenschaftlich fundiert diskutiert werden. Schulen, Eltern und Gesundheitsbehörden sind in der Pflicht, nicht zu verharmlosen, sondern zu informieren.

Dopaminspiegel schuld an Cannabispsychosen?

underground. 

(aka Spektr_, Spektrmusic...)

Old & New things, accross all my projects.

LIFE IS SHORT

I WANT YOU TO HEAR WHAT I HEAR

hanf-magazin.com ist das größte deutschsprachige Magazin zum Thema Hanf.

New tracks tagged #Neurotransmitter